Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 32

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 32
---
 in the first six months of 2024 compared to first six months of 2025.

Net cash used in financing activities is primarily related to the purchase of treasury shares, exercise of warrants, lease payments, and payment of withholding taxes on behalf of employees on net settled Restricted Stock Units (RSUs). The $106 million decrease in net cash used in financing activities between the periods is primarily driven by $111 million decreased cash paid for the purchase of treasury shares during the first six months of 2025 compared to the first six months of 2024 due to the timing of share repurchases. This decrease was partly offset by lower proceeds from the exercise of warrants of $4 million, with $7 million received in the first six months of 2025 as compared to $11 million in the first six months of 2024.

Genmab’s USD denominated marketable securities represented 75% of Genmab’s total marketable securities as of June 30, 2025, compared to 76% as of December 31, 2024.

Cash and cash equivalents included short-term marketable securities of $122 million as of June 30, 2025, compared to $11 million as of December 31, 2024. In accordance with our accounting policy, securities

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 21/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
purchased with a maturity of less than ninety days at the date of acquisition are classified as cash and cash equivalents.

Refer to Note 5 - Financial Instruments in this interim report for further details about our marketable securities.

Balance Sheet As of June 30, 2025, total assets were $6,464 million compared to $6,414 million on December 31, 2024. As of June 30, 2025, assets were mainly comprised of $355 million of goodwill and $1,752 million of other intangible assets, primarily made up of assets acquired in the ProfoundBio acquisition, marketable securities of $1,603 million, current receivables of $998 million, and cash and cash equivalents of $1,296 million. The current receivables consist primarily of